August 7, 2020 8:43pm

The question continues, are we pre-booked on the roller-coaster?

Pre-open indication results: 7 HITs and 3 MISS

Week in review …

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector.  I say today what others won't, so you can do what others can't; I put into context what is relevant for investors

Subscription is coming, my gift to you however, I've kept RMi subscription FREE during these COVID-19 and volatile times!

The Dow closed UP +46.50 points (+0.17%), the S&P closed UP +2.12 points (+0.06 %) while the NASDAQ closed DOWN -97.09 points (-0.87%)

 

Pre-open indication results: 7 HITS < Editas Medicine (EDIT -$2.13), Intellia therapeutics (NTLA -$0.16), Global Blood Therapeutics (GBT -$0.22), Mesoblast (MESO +$0.54), BioLife Solutions (BLFS +$0.35), Brainstorm Cell Therapy (BCLI +$0.64), Sage Therapeutics (SAGE +$0.70) and 3 MISS < uniQure NV (QURE -$0.54), Biostage (BSTG -$0.20), CRISPR Therapeutics (CRSP -$3.13),

 

Henry’omics:

The Dow and S&P 500 eked out small gains while the Nasdaq staggered on Friday, shaking off concerns over rising U.S.-China tensions and ongoing coronavirus stimulus negotiations that have fallen apart.

  • Yet, the U.S. economy added 1.763 million jobs in July, the Labor Department said Friday. Economists polled by expected a gain of 1.4 million.
  • The U.S. unemployment rate was also better than expected, falling to 10.2%.

This a.m. I stated in this a.m.’s newsletter – RegMed Investors’ (RMi) pre-open: jobs report and executive orders creates anxiety in markets … https://www.regmedinvestors.com/articles/11491

 

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Friday opened positive at 17/15 and 3 flats, stayed positive at the mid-day at 28/4 and 3 flats, closing positive at 21/11 and 3 flats;
  • Thursday opened negative at 11/21 and 3 flats, stayed negative at the mid-day at 11/22 and 2 flats, closing negative at 11/23 and 1 flat;
  • Wednesday opened positive at 17/14 and 4 flats, stayed positive at the mid-day at 19/15 and 1 flat, closing positive at 19/15and 1 flat;
  • Tuesday opened negative at 8/25 and 2 flats, stayed negative at the mid-day at 13/21 and 1 flat, closing negative at 13/20 and 2 flats;
  • Monday opened positive at 27/6 and 2 flats, stayed positive at the mid-day at 25/3 and 2 flats, closing positive at 31/1 and 3 flats;

 

Key metrics:

  • Sector volume was LOW with 1 of the 21-upside having higher than the 3-month average volume and the 2 of 11-downside having higher than the 3-month average volume;
  • Friday’s percentage (%) of the 21-upside were +0.17% (MDXG) to +8% (BSTG) while the 11-downside ranged -0.34% (GBT) to -5.78% (EDIT); 

 

Hammered in today’s market:

  • CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Regenxbio (RGNX), Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) to name 5 of the 11 declining of the 35 covered

Jumping with share pricing momentum:

  • Sage Therapeutics (SAGE), Adverum Biotechnologies (ADVM), Brainstorm Cell Therapeutics (BCLI), Sangamo Therapeutics (SGMO) to name 5 of the 21 trading up of 35 covered

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB closed down -0.39% and XBI also closed up +0.10%
  • Thursday, the IBB closed down -0.38% and XBI also closed down -0.51%
  • Wednesday, the IBB closed down -0.29% and XBI also closed up +0.72%
  • Tuesday, the IBB closed down -0.64% and XBI also closed down -0.31%
  • Monday, the IBB closed up +3.13% and XBI also closed up +4.20%

 

Friday’s (10 of 21) incliners:

  • Sage Therapeutics (SAGE +$0.70 after Thursday’s -$0.70, Wednesday’s +$0.91 and Tuesday’s +$3.37);
  • Adverum Biotechnologies (ADVM +$0.67);
  • Brainstorm Cell Therapeutics (BCLI +$0.64 after Thursday’s -$0.96, Wednesday’s -$0.28 and Tuesday’s -$0.69);
  • Sangamo Therapeutics (SGMO +$0.61 after Thursday’s +$0.22);
  • Cellectis SA (CLLS +$0.58 after Thursday’s -$0.87 and Wednesday’s +$0.52);
  • Vericel (VCEL +$0.57 after Thursday’s -$0.75, Wednesday’s -$0.90 and Tuesday’s -$0.37);
  • Mesoblast (MESO +$0.54);
  • Fate Therapeutics (FATE +$0.41 after Thursday’s +$0.58);
  • BioLife solutions (BLFS +$0.35);
  • Ultragenyx (RARE +$0.28 after Thursday’s +$1.10 after Wednesday’s -$0.71, Tuesday’s +$0.63 and Monday’s +$5.38);

Friday’s (11 of 11) decliners:

  • CRISPR Therapeutics (CRSP -$3.13 after Thursday’s -$1.57);
  • Editas Medicine (EDIT -$2.13 after Thursday’s +$4.35, Wednesday’s +$0.61, Tuesday’s +$0.31 and Monday’s +$2.21);
  • Regenxbio (RGNX -$1.28 after Thursday’s +$0.11, Wednesday’s +$0.45 and Tuesday’s -$0.59);
  • Alnylam Pharmaceuticals (ALNY -$0.59 after Thursday’s -$6.32, Wednesday’s -$2.32, Tuesday’s +$0.46 and Monday’s +$6.54);
  • uniQure NV (QURE -$0.54 after Thursday’s +$0.01 and Wednesday’s -$0.42);
  • Bellicum Pharmaceuticals (BLCM -$0.43);
  • bluebird bio (BLUE -$0.36 after Thursday’s +$1.78, Wednesday’s -$0.38, Tuesday’s -$0.34 and Monday’s +$2.08);
  • Ionis Pharmaceuticals (IONS -$0.30 after Thursday’s -$0.97 and Wednesday’s -$2.32);
  • Global Blood Therapeutics (GBT -$0.22 after Thursday’s -$3.86, Wednesday’s -$0.86, Tuesday’s -$1.72 and Monday’s +$3.00);
  • Intellia Therapeutics (NTLA -$0.16 after Thursday’s +$0.34);
  • Pluristem (PSTI -$0.13 after Thursday’s -$0.79);

Closing flat: 3 – ReNeuron (RENE.L), Verastem (VSTM) and Stemline Therapeutics (STML – acquired)

 

Percentage (%) movement/range statistics: comparisons

  • Friday’s percentage (%) of the 21-upside were +0.17% (MDXG) to +8% (BSTG) while the 11-downside ranged -0.34% (GBT) to -5.78% (EDIT); 
  • Thursday’s percentage (%) of the 11-upside were +0.02% (QURE) to +14.68% (BSTG) while the 23-downside ranged -0.38% (ATHX) to -10.38% (CLBS); 
  • Wednesday’s percentage (%) of the 19-upside were +0.31% (NTLA) to +6.12% (CLBS) while the 15-downside ranged -0.06% (CRSP) to -5.35% (VCEL); 
  • Tuesday’s percentage (%) of the 13-upside were +0.08% (IONS) to +7.52% (MESO) while the 20-downside ranged -0.10% (BLFS) to -8.90% (ADRO); 
  • Monday’s percentage (%) of the 31-upside were +1.33% (AGTC) to +8.24% (CRSP) while the 1-downside was -14.80% (BSTG); 

 

Sentiment and a few daily indicators:

We are still waiting for clues on a new coronavirus stimulus package …

  • Friday 4.88 cases
  • Thursday 4.85 cases
  • Wednesday 4.7 cases
  • Tuesday 4.71 cases
  • Monday 4.66 cases,

Friday’s death rate totaled 160,111 after Thursday’s 159,433, Wednesday’s 157,186 after Tuesday’s 155,478 and Monday’s 154,860 <Johns Hopkins University>

 

Stats:

Upside volume: 

  • Friday: 1 out of the 21-upside had higher than the 3-month average volume;
  • Thursday: 6 out of the 11-upside had higher than the 3-month average volume;
  • Wednesday: 2 out of the 19-upside had higher than the 3-month average volume;
  • Tuesday: 2 out of the 13-upside had higher than the 3-month average volume;
  • Monday: 8 out of the 31-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -0.44 points or -1.94% at 22.21
  • Thursday was down -0.34 points or -1.48% at 22.65
  • Wednesday was down -0.77 points or -3.24% at 22.99
  • Tuesday was down -0.52 points or -2.14% at 23.76
  • Monday was down -0.18 points or -0.74% at 24.28

Downside volume:

  • Friday: 2 out of the 11-downside had higher than the 3-month average volume;
  • Thursday: 4 out of the 23-downside had higher than the 3-month average volume;
  • Wednesday: 5 out of the 15-downside had higher than the 3-month average volume;
  • Tuesday: 2 out of the 20-downside had higher than the 3-month average volume;
  • Monday: 1 out of the 1-downside had higher than the 3-month average volume;

 

August, the second month of Q3 …

  • Friday closed positive with 21 advancers, 11 decline and 3 flats
  • Thursday closed negative with 11 advancers, 23 decline and 1 flat
  • Wednesday closed positive with 19 advancers, 15 decline and 1 flat
  • Tuesday closed negative with 13 advancers, 20 decline and 2 flats
  • Monday (8/3) closed positive with 31 advancers, 1 decline and 3 flats

 

The Bottom line:  It’s an honor to be considered the “canary in the (sectors) coal mine”!  I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!

Again … I remind those who utilize stock “moves” of “managing” pricing of two words - SEC and transparency! I once worked for U.S. government agencies and I admit they were slow but, they delivered a powerful blow!

The remainder of the month’s trading sessions will be critical for the RegMed, cell and gene therapy sector which will establish whether today’s upside reaction is short-lived as a 1-day aberration followed by downside move or moves with an on-coming fundamental corrections 

RMi outlines preludes and aftermaths defining the daily dosage of facts and objectivity.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.